The Myocardial Fibrosis drugs in development market research report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myocardial Fibrosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Myocardial Fibrosis by 13 companies/universities/institutes. The top development phase for Myocardial Fibrosis is preclinical with nine drugs in that stage. The Myocardial Fibrosis pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Myocardial Fibrosis pipeline products market are: Invivosciences, ZyVersa Therapeutics and Vectus Biosystems.

The key targets in the Myocardial Fibrosis pipeline products market include Rho Guanine Nucleotide Exchange Factor 12 (Leukemia Associated RhoGEF or ARHGEF12), NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.), and Myosin ATPase (Actomyosin or ATP Phosphohydrolase or EC 5.6.1.8).

The key mechanisms of action in the Myocardial Fibrosis pipeline product include 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) Antagonist with one drug in Discovery. The Myocardial Fibrosis pipeline products include two routes of administration with the top ROA being Oral and five key molecule types in the Myocardial Fibrosis pipeline products market including Small Molecule, and Oligonucleotide.

Myocardial Fibrosis overview

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea, and fatigue.

For a complete picture of Myocardial Fibrosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.